Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amneal Pharmaceuticals, Inc. - Class A Common Stock
(NY:
AMRX
)
N/A
UNCHANGED
Last Price
Updated: 7:00 PM EST, Dec 26, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
3
4
5
6
7
Next >
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
November 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...
Via
Benzinga
Topics
Retirement
Exposures
Pension
Amneal Reports Third Quarter 2021 Financial Results
November 03, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Releases Inaugural Corporate Responsibility Report Highlighting Our Impact as a Socially Responsible Company
November 02, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA
October 27, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Mark Cuban-Owned Company To Launch Pharmacy Benefit Management Services
October 25, 2021
Billionaire investor Mark Cuban is funding a new company focused on selling generic pharmaceuticals at a transparent fixed-rate markup. What Happened: The Mark Cuban Cost Plus...
Via
Benzinga
Amneal to Report Third Quarter 2021 Results on November 3, 2021
October 06, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Virtually Participate at Morgan Stanley 19th Annual Global Healthcare Conference
September 07, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
August 26, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
COVID-19
22 Stocks Moving in Thursday's Pre-Market Session
August 26, 2021
Gainers Good Works Acquisition Corp. (NASDAQ: GWAC) rose 29.8% to $13.01 in pre-market trading. Good Works Acquisition and Cipher Mining reported shareholder approval of business...
Via
Benzinga
Amneal's Parkinson's Candidate Shows Efficacy In Pivotal Trial
August 26, 2021
Amneal Pharmaceuticals Inc (NYSE: AMRX) announced topline data from the Phase 3 RISE-PD trial evaluating IPX-203 in patients with Parkinson's disease who have...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
August 25, 2021
Gainers Ascendis Pharma (NASDAQ:ASND) st...
Via
Benzinga
Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
August 25, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
August 25, 2021
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)...
Via
Benzinga
Exposures
COVID-19
Amneal Announces Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
August 23, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Pharmaceuticals, inc (AMRX) Q2 2021 Earnings Call Transcript
August 09, 2021
AMRX earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Amneal Q2 Earnings Tops Estimates; Backs FY21 Guidance
August 09, 2021
Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q2 revenue of $535 million, an increase of 15% Y/Y, beating the consensus of $523.25 million. Sales growth was driven by...
Via
Benzinga
Amneal Pharmaceuticals: Q2 Earnings Insights
August 09, 2021
Shares of Amneal Pharmaceuticals (NYSE:AMRX) moved higher by 0.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share...
Via
Benzinga
Amneal Reports Second Quarter 2021 Financial Results
August 09, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
July 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated...
Via
Benzinga
Amneal Receives Approval for Generic TobraDex®
July 19, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Report Second Quarter 2021 Results on August 9, 2021
July 15, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal's Avastin-Referred Biosimilar Under FDA Review For Colorectal Cancer
June 17, 2021
The FDA has accepted for review Amneal Pharmaceuticals Inc's (NYSE: AMRX) marketing application seeking approval for Bevacizumab, under Section 351(k) pathway...
Via
Benzinga
Exposures
Product Safety
Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab
June 17, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches
June 07, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Virtually Participate at Upcoming Investor Conferences
May 14, 2021
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2021 Earnings Call Transcript
May 07, 2021
AMRX earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
12 Health Care Stocks Moving In Friday's After-Market Session
May 07, 2021
Gainers Protagenic Therapeutics (NASDAQ:PTIX
Via
Benzinga
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
May 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.